Dyax - Advancing Novel Biotherapeutics

Dyax.com: Products and Pipeline

Internal Pipeline

 DiscoveryPreclinical  Phase 1  Phase 2  Phase 3   Market
 

  In development/Approved     Preparing to initiate     Out-licensed

 


1.Please visit www.KALBITOR.com for Important Safety Information and Full Prescribing Information including Boxed Warning and Medication Guide  2.Partenered with Cubist Pharmaceuticals in North America and Europe  3.Retinal Vein Occlusion (RVO). Partnered with Fovea Pharmaceuticals in EU  4.Licensed to sanofi aventis  *Compassionate-use of DX-88 in AAE  **Investigator-sponsored study for DX-88 in drug-induced angioedema
KALBITOR® (ecallantide)1  
Hereditary Angioedema (HAE)
 
   
DX-88  
On-pump cardiothoracic surgery (CTS)2  
Acquired angioedema (AAE)*  
ACE inhibitor-induced angioedema**  
Retinal vein occlusion (RVO)induced macular edema3  
   
DX-2240  
Oncology4  
   
DX-2400  
Oncology  
   
Multiple Programs  
Ongoing programs focused in oncology and inflammation  
   

You are now leaving Dyax.com.
The web site you are about to visit is neither owned nor controlled by Dyax Corp. Dyax Corp. is not responsible for the content, products or services on this site.

Do you wish to continue?